ONCO/Reveal™
Lung and Colon Cancer Genetic Test
What is Lung and Colon Cancer Genetic Test?
It detects numerous gene regions of interest for researchers looking to explore the genetic sequences of both germline and formalin-fixed paraffin-embedded (FFPE) DNA from lung cancer and colon cancer samples. Utilizing SLIMamp® (stem-loop inhibition mediated amplification) allows researchers to amplify regions of interest in a simple, multiplex reaction for subsequent sequencing on a sequencer using a paired-end read length of 150 (2×150).
The majority of lung cancers (~85%) are classified as non-small cell lung cancer (NSCLC).[4] Nearly half of NSCLC cases are associated with point mutations, or other biomarkers such as EGFR. The prevalence of these biomarkers varies between ethnic populations. The proportion of EGFR mutations is much higher in NSCLC patients in Asia (30-40%) than in NSCLC patients in the US and Europe (10-15%).[1]
non-small cell lung cancer (NSCLC)
85%
35-40% of patients with CRC found activating mutations in KRAS
10-15%
The proportion of EGFR mutations
30-40%
[1] Ellison, G., Zhu, G., Moulis, A., Dearden, S., Speake, G., & McCormack, R. (2012). EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. Journal of Clinical Pathology, 66(2), 79–89. https://doi.org/10.1136/jclinpath-2012-201194
An approximation of 35-40% of patients with CRC found activating mutations in KRAS. Therefore, KRAS-mutation status can be a predictive biomarker for response to anti-EGFR-targeted therapy. There is now strong evidence that cetuximab and panitumumab are effective to patients with CRC whose tumours carry a wild-type KRAS gene. [2]
Patients with CRC found activating mutations in KRAS
35-40%
[1] Ellison, G., Zhu, G., Moulis, A., Dearden, S., Speake, G., & McCormack, R. (2012). EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. Journal of Clinical Pathology, 66(2), 79–89. https://doi.org/10.1136/jclinpath-2012-201194
Target
Researchers looking to explore the genetic sequences of both germline and formalin-fixed Paraffin-embedded (FFPE) DNA from lung cancer and colon cancer samples.
Table 1. Gene List
| AKT1 | EGFR | FGFR2 | NOTCH | STK11 |
| ALK | ERBB2 | FGFR3 | NRAS | TP53 |
| BRAF | ERBB4 | KRAS | PIK3CA | |
| CTNNB1 | FBXW7 | MAP2K1 | PTEN | |
| DDR2 | FGFR1 | MET | SMAD4 |
|
Items
|
Lung and Colon Cancer Genetic Test
|
|---|---|
|
Content
|
22 genes related to NSCLC and CRC tumour (please refer to table 1 for details)
|
|
Sequencing Platform
|
NGS
|
|
Sequencing Type
|
Amplicon based sequencing
|
|
Variants Type
|
SNVs, indel
|
|
Sample Type
|
FFPE
|
|
TAT
|
7 working days**
|
Workflow
STEP 01
Pre-sales consultation
STEP 02
Sign the consent form, collect paraffin-embedded sections
STEP 03
Send the specimen to the laboratory
STEP 04
Analyse the experimental data
STEP 05
A total of 7 working days to complete the report**
**Only applicable to the sample that fulfil the QC requirements.